Mediastinal staging of lung cancer: Novel concepts

Kurt G. Tournoy, Steven M. Keller, Jouke T. Annema

Research output: Contribution to journalComment/debate

60 Scopus citations

Abstract

Clinical TNM staging is the standard method used to decide treatment for patients with non-small-cell lung cancer. Although integrated fluorodeoxyglucose (FDG) PET CT increases the accuracy of staging, it only guides direct tissue sampling. Histological assessment of mediastinal lymph nodes has traditionally been done with mediastinoscopy, a surgical procedure. Endobronchial and oesophageal ultrasound-guided lymph node sampling have been assessed as additions or alternatives to mediastinoscopy. We review endosonography and surgical staging, and show that both have a place in the mediastinal staging of lung cancer. We conclude that mediastinal tissue staging should preferentially start with a complete endosonographic assessment. A surgical mediastinoscopy should be reserved for those in whom the endosonography result is negative. Further refinement of this recommendation is likely in the near future because data suggest that the confirmatory mediastinoscopy is particularly useful for patients with enlarged or FDG-avid lymph nodes.

Original languageEnglish (US)
Pages (from-to)e221-e229
JournalThe Lancet Oncology
Volume13
Issue number5
DOIs
StatePublished - May 1 2012

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Mediastinal staging of lung cancer: Novel concepts'. Together they form a unique fingerprint.

  • Cite this

    Tournoy, K. G., Keller, S. M., & Annema, J. T. (2012). Mediastinal staging of lung cancer: Novel concepts. The Lancet Oncology, 13(5), e221-e229. https://doi.org/10.1016/S1470-2045(11)70407-7